<DOC>
	<DOCNO>NCT02910063</DOCNO>
	<brief_summary>This phase 2/3 open label , multicenter trial test blinatumomab monotherapy treatment subject Relapsed/Refractory ( R/R ) aggressive B-NHL achieve CMR 2 cycle standard platinum-based chemotherapy regimen administer S1 . This study incorporate multiple interim analysis futility , efficacy , unblinded sample-size re-estimation . In phase 3 part study , blinatumomab compare Investigator 's Choice chemotherapy .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Blinatumomab Subjects With Relapsed/Refractory ( R/R ) Aggressive B-Cell NHL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Biopsy proven aggressive Bcell NonHodgkin Lymphoma ( BNHL ) , include diffuse large Bcell lymphoma ( DLBCL ) otherwise specify ( NOS ) , follicular lymphoma Grade 3B , Primary Mediastinal BCell Lymphoma , Tcell rich Bcell lymphoma , DLBCL represent transformation indolent nonHidgkin 's Lymphoma ( NHL ) , ( include follicular , marginal zone , lymphoplasmacytoid lymphoma ) exclude chronic lymphocytic leukemia Hodgkin Lymphoma . The following histology eligible : Lymphoblastic lymphoma Burkitt lymphoma Any histology specifically mention must discuss medical monitor . Refractory ( prior complete metabolic response ( CMR ) ) relapse ( prior CMR ) follow front line treatment standard multiagent chemotherapy contain anthracycline AND approve antiCD20 agent . For refractory disease , PET positivity demonstrate less 6 week radiotherapy Biopsy evidence relapse disease . Received 2 cycle standard care platinumbased chemotherapy S1 set response progressive metabolic disease ( PMD ) , metabolic response ( NMR ) , partial metabolic response ( PMR ) centrally assess PET CT scan receive least 1 cycle S1 chemotherapy evidence progressive disease ( PD ) centrally assess Radiographically measurable disease demarcate nodal lesion least 1.5 cm large dimension target extranodal lesion least 1.0 cm large dimension Eastern Cooperative Oncology Group performance status less equal 2 Potentially eligible high dose chemotherapy ( HDT ) autologous hematopoietic stem cell transplant ( HSCT ) Laboratory parameter : Hematology : Absolute neutrophil count ( ANC ) ≥ 1.0 x 109/L Platelets ≥ 75 x 109/L Chemistry : Creatinine clearance ≥ 50 mL/min Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &lt; 3X upper limit normal ( ULN ) Total bilirubin ( TBL ) &lt; 2x ULN ( unless Gilbert 's disease liver involvement lymphoma ) CMR follow S1 chemotherapy Treatment within 30 day prior randomization another investigational device drug study ( y ) . Prior antiCD19directed therapy Prior HDT autologous HSCT Prior allogeneic HSCT Clinically relevant central nervous system ( CNS ) pathology epilepsy , paresis , aphasia , stroke , severe brain injury , dementia , Parkinson 's disease , cerebellar disease , organic brain syndrome , psychosis Evidence CNS involvement NHL Known infection human immunodeficiency virus chronic infection hepatitis B virus ( hepatitis B surface antigen positive ) hepatitis C virus ( anti hepatitis C virus positive ) History malignancy BNHL within past 3 year exception : Malignancy treat curative intent know active disease present ≥ 3 year enrollment Adequately treated nonmelanoma skin cancer lentigo maligna Adequately treated cervical carcinoma situ Adequately treat breast ductal carcinoma situ Prostatic intraepithelial neoplasia without evidence prostate cancer Adequately treat urothelial papillary noninvasive carcinoma carcinoma situ Known sensitivity immunoglobulins component administer dose . Subject likely available complete protocolrequired study visit procedure , and/or comply require procedure . History evidence clinically significant disorder , condition disease ( exception outline ) would pose risk subject safety interfere study evaluation , procedures completion . Female subject pregnant breastfeed plan become pregnant breastfeed , childbearing potential unwilling use effective method contraception receiving , additional 48 hour last dose blinatumomab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma</keyword>
	<keyword>Blinatumomab</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Standard Care</keyword>
	<keyword>SOC</keyword>
	<keyword>Cancer</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>